Probiotics Powder
Bifidobacterium Breve powder
Bifidobacterium breve powder is a high-quality probiotic isolated and cultured from the intestinal tract of healthy infants or adults, processed into a highly active raw powder via freeze-drying technology.It can efficiently ferment human milk oligosaccha
Description
What are the benefits of Bifidobacterium breve for the infant gut?
Bifidobacterium breve is a core beneficial bacterium in the gut of breastfed infants, and its abundance directly affects intestinal health and immune development in young children. Studies have shown that infants with higher levels of Bifidobacterium breve have nearly a 5-fold lower risk of developing eczema, allergies, and asthma by the age of 2.
Specifically, Bifidobacterium breve provides significant benefits to the infant gut through multiple mechanisms:
1.Establishing a healthy gut microbiota foundation
As a dominant species in the infant gut, Bifidobacterium breve efficiently breaks down oligosaccharides in breast milk to produce short-chain fatty acids, lowers intestinal pH, inhibits the growth of harmful bacteria, and helps formula-fed infants establish a gut microbiota structure similar to that of breastfed infants.
2.Relieving colic and reducing crying
Multiple clinical studies have confirmed that supplementation with Bifidobacterium breve (such as strains M-16V, B632, CECT7263, etc.) significantly reduces the incidence of infant colic and shortens daily crying time by approximately 60%, with effects superior to conventional medications.
3.Reducing the risk of necrotizing enterocolitis (NEC)
Bifidobacterium breve M-16V is used in more than 100 neonatal intensive care units in Japan to support growth and development in preterm infants. It significantly lowers the risk of infection, sepsis, and NEC in very low and extremely low birth weight preterm infants.
4.Preventing and improving allergic symptoms
Clinical studies show that synbiotic formulations combining Bifidobacterium breve M-16V with prebiotics significantly increase the proportion of Bifidobacteria in the gut and reduce the risk of eczema and atopic dermatitis.Bifidobacterium breve CCFM1078 alleviates early atopic dermatitis through three synergistic mechanisms: activating the AhR signaling pathway, correcting Th1/Th2 immune imbalance, and reshaping the gut microbiota structure.
| Product Name: | Bifidobacterium breve Powder |
| Strain name: | Bifidobacterium breve |
| Strain identification: | Characteristic by API 50CH&16S rDNA |
| Type: | Freeze dried powder |
| Packing: | 1kg/bag, 5kg/bag in cold-chain package |
| Storage: | Package sealed at 4℃ or refrigeration - 18℃ |
| Shelf life: | 24 months from date of production |
| Certfication: | NSF, HACCP, ISO9001, Kosher, HALAL |
| Documents support: | Genetic identification report |
| IDA deposit certificate | |
| Certificate of analysis | |
| Stability study report | |
| Anti-bile salt & Anti gastro-acid study report | |
| Antibiotic sensitivity test certificate | |
| Safety study report | |
| Microbial Enumeration method |
| Descrption: | Fine powder, no caking, no abnormal odor, no visible foreign bod |
| Color: | White to light yellow |
| Mositure: | NMT 5.0% |
| Water activity: | < 0.12% |
| Viable cell count: | NLT 500 billion cfu/gram |
| Non LAB count: | < 5000 cfu/g |
| Yeast &mould: | NMT 50 cfu/g |
| Coliform: | < 10 cfu/g |
| Pathogenic bacteria: | Negative |
| Lead(Pb): | NMT 0.5 mg/kg |
| Arsenic(As): | NMT 0.5 mg/kg |
| Cadmium(Cd): | NMT 1.0 mg/kg |
| Mercury(Hg): | NMT 0.1 mg/kg |
1. Establishes a healthy gut microbiota foundation
As a dominant strain in the gut of breastfed infants, Bifidobacterium breve can efficiently break down human milk oligosaccharides to produce short-chain fatty acids, lower intestinal pH, inhibit the growth of harmful bacteria, and help formula-fed infants establish a gut microbiota structure similar to that of breastfed infants.
2. Relieves colic and reduces crying
Multiple clinical studies have confirmed that Bifidobacterium breve (such as M-16V, B632, CECT7263) can significantly reduce the incidence of infant colic and shorten daily crying time by approximately 60%, with effects superior to conventional medications.
3. Reduces the risk of necrotizing enterocolitis
Bifidobacterium breve M-16V is used in many neonatal intensive care units in Japan. It can significantly reduce the risk of infection, sepsis and necrotizing enterocolitis in very low/extremely low birth weight preterm infants.
4. Prevents and improves allergic symptoms
Bifidobacterium breve M-16V combined with prebiotics can reduce the risk of eczema and atopic dermatitis; strain CCFM1078 alleviates early atopic dermatitis by activating the AhR signaling pathway and correcting Th1/Th2 immune imbalance.
5. Enhances intestinal barrier and immune regulation
It strengthens intestinal barrier function and reduces intestinal permeability by upregulating the expression of tight junction proteins. At the same time, it promotes the secretion of secretory immunoglobulin A (sIgA) and improves mucosal immune defense in infants and young children.
6. Promotes nutrient absorption and digestion
It produces β-galactosidase to help break down lactose and improve lactose intolerance. It participates in the synthesis of B vitamins and promotes the absorption of minerals such as calcium and iron by lowering intestinal pH.
1. Clear strain origin
Bifidobacterium breve is a natural commensal bacterium isolated from the intestinal tract of healthy infants or adults, with clear strain designations (such as M-16V, B632, CECT7263, CCFM1078). Whole-genome sequencing and 16S rRNA identification reports are available.
2. Excellent utilization of human milk oligosaccharides
It possesses a unique HMO metabolic gene cluster, enabling efficient utilization of various oligosaccharides in breast milk as carbon sources, giving it a distinct colonization advantage in the gut of breastfed infants.
3. Strong acid and bile tolerance and colonization ability
It has good tolerance to gastric acid and bile, can pass through the gastrointestinal tract as viable bacteria, and stably colonize the intestinal tract of infants and young children to ensure probiotic effects.
Q1: Can Bifidobacterium breve relieve infant colic?
A: Yes. Clinical studies confirm that strains such as Bifidobacterium breve M-16V, B632 and CECT7263 can significantly reduce the incidence of infant colic and decrease daily crying duration by approximately 60%, with better efficacy than conventional medications such as simethicone.
Q2: What benefits does Bifidobacterium breve offer for preterm infants?
A: Bifidobacterium breve M-16V is used in more than 100 neonatal intensive care units in Japan. It can significantly reduce the risk of infection, sepsis and necrotizing enterocolitis in very low/extremely low birth weight preterm infants, and improve their growth and development.
Q3: Can Bifidobacterium breve prevent allergies?
A: Yes. Studies show that infants with higher levels of Bifidobacterium breve have nearly a 5-fold lower risk of developing eczema, allergies and asthma by the age of 2. Bifidobacterium breve M-16V combined with prebiotics can reduce the risk of eczema, and strain CCFM1078 can alleviate early atopic dermatitis.
Q4: How is the processing stability of Bifidobacterium breve?
A: Bifidobacterium breve is sensitive to oxygen and high temperatures. Modern industry uses freeze-drying plus microencapsulation technology to significantly improve stability. It is suitable for infant formula (dry blending process), drops and powders. Processing temperature should be controlled below 40°C and high-humidity environments should be avoided.
Q5: What dosage forms is Bifidobacterium breve suitable for?
A: It is suitable for infant formula (dry blending), probiotic drops, powders and capsules. Dry blending or low-temperature processing is recommended, with high-temperature sterilization steps avoided.
